Proteomic mapping of proteins released during necrosis and apoptosis from cultured neonatal cardiac myocytes

Abstract

Cardiac injury induces myocyte apoptosis and necrosis, resulting in the secretion and/or release of intracellular proteins. Currently, myocardial injury can be detected by analysis of a limited number of biomarkers in blood or coronary artery perfusate. However, the complete proteomic signature of protein release from necrotic cardiac myocytes is unknown. Therefore, we undertook a proteomic-based study of proteins released from cultured neonatal rat cardiac myocytes in response to H2O2 (necrosis) or staurosporine (apoptosis) to identify novel specific markers of cardiac myocyte cell death. Necrosis and apoptosis resulted in the identification of 147 and 79 proteins, respectively. Necrosis resulted in a relative increase in the amount of many proteins including the classical necrotic markers lactate dehydrogenase (LDH), high-mobility group B1 (HMGB1), myoglobin, enolase, and 14-3-3 proteins. Additionally, we identified several novel markers of necrosis including HSP90, α-actinin, and Trim72, many of which were elevated over control levels earlier than classical markers of necrotic injury. In contrast, the majority of identified proteins remained at low levels during apoptotic cell death, resulting in no candidate markers for apoptosis being identified. Blotting for a selection of these proteins confirmed their release during necrosis but not apoptosis. We were able to confirm the presence of classical necrotic markers in the extracellular milieu of necrotic myocytes. We also were able to identify novel markers of necrotic cell death with relatively early release profiles compared with classical protein markers of necrosis. These results have implications for the discovery of novel biomarkers of necrotic myocyte injury, especially in the context of ischemia-reperfusion injury.

Comparative mRNA and MicroRNA Profiling during Acute Myocardial Infarction Induced by Coronary Occlusion and Ablation Radio-Frequency Currents

“…In the last decade, there have been several efforts to dissect out cardiac mRNA and proteome in a wide array of cardiovascular diseases (McGregor and Dunn, 2006) using different animal models or plasma samples collected from human patients (Seenarain et al, 2010; Haas et al, 2011; Silbiger et al, 2011; Drastichova et al, 2012; Chowdhury et al, 2013; Marshall et al, 2014; Petriz and Franco, 2014). While novel biomarkers were identified from some of these studies (Haas et al, 2011; Silbiger et al, 2011; Chowdhury et al, 2013), authors reported general alterations in the cardiac transcriptome and proteome profile that suggested changes in Ca2+ handling proteins (Seenarain et al, 2010), energy metabolism proteins (Jin et al, 2006; Meng et al, 2009), and mediators of apoptotic signaling (Drastichova et al, 2012; Marshall et al, 2014; Petriz and Franco, 2014). …”

Transformative Impact of Proteomics on Cardiovascular Health and Disease

“…7 The development of more sensitive troponin assays is another example of how proteomics has enabled the development of improved diagnostic methods, 8 with high-sensitivity troponin assays permitting earlier diagnosis of acute coronary syndromes. 9,10 MS was an integral part of the harmonization of cardiac troponin I assays, which was accomplished by development of a human cardiac standard to calibrate troponin assays.…”

Proteomics Research in Cardiovascular Medicine and Biomarker Discovery

“…Clinically useful biomarkers can include circulating proteins that have been secreted or leaked directly into the plasma from resident cells (e.g., myocytes) following diseases or injuries (15), and are thus spatially uncoupled from the transcript change at the tissue of origin. The tissues of origin of circulating proteins may be unknown, inaccessible, or invasive to procure, making it impractical to hunt for these potential biomarkers via transcript measurements, instead of protein measurements.…”